American College of Clinical Pharmacy
      Search      Cart
         

2022 ACCP/ASHP BCACP Clinical Sessions

 


ACCP   ASHP

 

ACCP collaborates with ASHP on Ambulatory Care Pharmacy activities.

 

ASHP members, please visit www.rxcertifications.org to receive member pricing.

 

Series Overview

The 2022 ACCP/ASHP BCACP Clinical Sessions are part of the professional development programs for recertification of the Board Certified Ambulatory Care Pharmacist and/or the Board Certified Geriatric Pharmacist approved by the Board of Pharmacy Specialties (BPS) and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP).

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants' skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

Release date: December 14, 2022
Specialty Recertification credit expiration date: December 12, 2023
ACPE credit expiration date: December 14, 2025

Program Content

The 2022 ACCP/ASHP BCACP Clinical Sessions are offered in four presentations. Each presentation focuses on a different Ambulatory Care Pharmacy/Geriatric Pharmacy topic that is highly relevant for day-to-day practice. Topics include antimicrobial stewardship, sleep disorders in older adults, Heart Failure with preserved Ejection Fraction (HFpEF), and treatment of Alzheimer’s and Parkinson’s.

BCACP Clinical Session
Don't Go Viral with Antibiotics – How Pharmacists Can Use Antimicrobial Stewardship to Help Check Resistance at the Door

Antimicrobial resistance is a rapidly growing problem, propagated by inappropriate antimicrobial utilization. Across the United States, health systems have improved use through establishment of antimicrobial stewardship programs as mandated by the 2016 CMS Core Elements. Government mandated antimicrobial stewardship requirements for outpatient facilities mirror those of inpatient facilities, and the high rates of antimicrobial use in these settings urgently calls for enhanced efforts in implementation of antimicrobial stewardship in outpatient settings. The session will focus on appropriate outpatient use of antimicrobial agents [e.g., when to use, dosing, duration] as well as novel methods of improving cost and outcomes.

BCACP/BCGP Clinical Session
Sweet Dream or Nightmare: Managing Sleep Complaints in Older Adults

The purpose of this session will be to review management strategies of common sleep complaints, examine newer literature in the arena and apply the guidance to clinical pharmacy practice. Insomnia continues to be a common health issue for older adults with the patient population being extremely prone to medication related problems. Obstructive sleep apnea (OSA) and restless leg syndrome (RLS) can both be complicating factors for a patient's insomnia and excessive daytime sleepiness. New guidelines published on RLS management now recommend alpha2-delta calcium channel ligands over dopamine agonists for first line treatment of chronic RLS. OSA continues to be a contributor to underlying chronic disease states such as hypertension and is frequently under documented on a patient's problem list. Participants will be empowered to tackle this potential nightmare in practice through evidence-based approaches.

BCACP/BCGP Clinical Session
Anything ARNI Can Do, SGLT2i Can Do Better? Debate of Pharmacologic Therapies in HFpEF

Heart Failure with preserved Ejection Fraction (HFpEF) affects between 1.1-5.5% of the general population, with a prevalence of > 10% in older adults (> 75 years of age). Patients with HFpEF suffer from significant morbidity and mortality, however traditional therapies used to manage Heart Failure with reduced Ejection Fraction (HFrEF), have failed to reduce morbidity or mortality in these patients. Recently, mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and angiotensin receptor blocker neprilysin inhibitors (ARNI) have demonstrated benefits in this population, but limitations in data pose questions regarding application to routine patient care. Further understanding related to patient selection, safe initiation and monitoring, and considerations for shared-decision making discussions (e.g., cost and adherence) is important for adequate therapy optimization, particularly in ambulatory settings and with older adult patients. This session will discuss an initial overview of HFpEF, the "traditional" approach to management, and gaps in patient care; a discussion of recently evaluated entities for HFpEF, including MRA, ARNI and SGLT2 inhibitors; and a case-based format.

BCACP/BCGP Clinical Session
Breaking Down Neurodegenerative Diseases: Pharmacy Updates in Managing Alzheimer's and Parkinson's

More than 6 million Americans are living with Alzheimer’s disease (AD) and another 1 million are living with Parkinson’s disease (PD). Advances have been made in the management of both illnesses; however, models suggest there may be barriers to their practical use. This session will address AD immunotherapies on the breakthrough pathway, focusing on the appropriate use of approved therapies, expectations for emerging therapies, potential barriers to use and subsequent place in therapy. The role of the pharmacist in closing gaps in screening, diagnosis, and treatment for AD will be emphasized. Furthermore, the session will address the place in therapy for new medications and formulations approved to treat motor, non-motor, and psychiatric complications of PD.

Faculty

Don't Go Viral with Antibiotics – How Pharmacists Can Use Antimicrobial Stewardship to Help Check Resistance at the Door

Wiyanna K. Bruck, Pharm.D., BCPS, BCIDP, BCPPS Wiyanna K. Bruck, Pharm.D., BCPS, BCIDP, BCPPS
Clinical Pharmacist/Assistant Professor of Pharmacy Practice
South College School of Pharmacy
Knoxville, Tennessee
 
Athena L.V. Hobbs, Pharm.D., BCIDP Athena L.V. Hobbs, Pharm.D., BCIDP
Infectious Diseases Clinical Manager Post Acute Medical
Cardinal Health Innovative Delivery Solutions
Dublin, Ohio
 
Monica V. Mahoney, Pharm.D., BCPS, BCIDP Monica V. Mahoney, Pharm.D., BCPS, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
Beth Israel Deaconess Medical Center
Boston, Massachusetts
 

Sweet Dream or Nightmare: Managing Sleep Complaints in Older Adults

Laura A. Schalliol, Pharm.D., BCACP, BCGP Laura A. Schalliol, Pharm.D., BCACP, BCGP
Associate Professor of Pharmacy Practice
PGY-1 Community-Based Residency Program Director
South College School of Pharmacy
Knoxville, Tennessee
 
Kimberly Zitko, Pharm.D., BCACP, BCGP Kimberly Zitko, Pharm.D., BCACP, BCGP
Assistant Professor of Pharmacy Practice
South College School of Pharmacy
Knoxville, Tennessee
 

Anything ARNI Can Do, SGLT2i Can Do Better? Debate of Pharmacologic Therapies in HFpEF

, Stormi Gale, Pharm.D., BCCP, BCPS Stormi Gale, Pharm.D., BCCP, BCPS
Clinical Pharmacist, Cardiology Subject Matter Expert
Novant Health Matthews Medical Center
Matthews, North Carolina
 
Alina Kukin, Pharm.D., BCCP Alina Kukin, Pharm.D., BCCP
Cardiology Clinical Pharmacy Specialist
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
 
Tracy E. Macaulay, Pharm.D., BCPS Tracy E. Macaulay, Pharm.D., BCPS
Clinical Pharmacist Specialist, Cardiology
Gill Heart Institute
University of Kentucky
Lexington, Kentucky
 

Breaking Down Neurodegenerative Diseases: Pharmacy Updates in Managing Alzheimer's and Parkinson's

Jenelle H. Montgomery, Pharm.D., BCACP, CPP Jenelle H. Montgomery, Pharm.D., BCACP, CPP
Clinical Pharmacist Practitioner
Duke University Hospital
Assistant Professor of Clinical Education
UNC Eshelman School of Pharmacy
Durham, North Carolina
 
Kristin Zimmerman, Pharm.D., CGP Kristin Zimmerman, Pharm.D., CGP
Associate Professor, Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University School of Pharmacy
Richmond, Virginia
 
Reviewers
  • Amie Blaszczyk, Pharm.D., BCGP, BCPS, FASCP
  • Holly L. Byrnes, Pharm.D., BCPS
  • Michelle L. Hilaire, Pharm.D., FCCP, BCPS, BCACP, CDE
  • Kristi Hofer, Pharm.D.
  • Adam Jackson, Pharm.D., BCPS
  • Karen L. Kier, Ph.D., BCPS, BCACP
  • Nicholas Leon, Pharm.D., BCACP, BCPS, FCPP
  • Maria Shin, Pharm.D., BCGP, BCPS
Financial Relationship Disclosures

Disclosures PDF

Target Audience and Learning Objectives

Target Audience
These recertification activities are intended for the Board Certified Ambulatory Care Pharmacist (BCACP) and the Board Certified Geriatric Pharmacist (BCGP) and those interested in antimicrobial stewardship, sleep disorders in older adults, Heart Failure with preserved Ejection Fraction (HFpEF), and treatment of Alzheimer's and Parkinson's.

Learning Objectives
Learning Objectives PDF

Continuing Pharmacy Education Credit

ACPEThe American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

BCACP Clinical Session
Don't Go Viral with Antibiotics – How Pharmacists Can Use Antimicrobial Stewardship to Help Check Resistance at the Door

Activity Number: 0217-9999-22-069-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

BCACP/BCGP Clinical Session
Sweet Dream or Nightmare: Managing Sleep Complaints in Older Adults

Activity Number: 0217-9999-22-068-H01-P
Contact Hours: 1.00
Activity Type: Application-Based Activity

BCACP/BCGP Clinical Session
Anything ARNI Can Do, SGLT2i Can Do Better? Debate of Pharmacologic Therapies in HFpEF

Activity Number: 0204-9999-22-331-H01-P
Contact Hours: 1.50
Activity Type: Application-Based Activity

BCACP/BCGP Clinical Session
Breaking Down Neurodegenerative Diseases: Pharmacy Updates in Managing Alzheimer's and Parkinson's

Activity Number: 0204-9999-22-287-H01-P
Contact Hours: 1.50
Activity Type: Application-Based Activity

Methods and CE Requirements

Continuing Pharmacy Education Credit

To be eligible to earn continuing pharmacy education credit, learners must purchase the product, review all content, successfully complete, submit and pass the web-based posttest associated with each module within the course by December 14, 2025. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

National Association of Boards of Pharmacy - CPE Monitor Service

Provided through the collaborative efforts of the National Association of Boards of Pharmacy (NABP), the Accreditation Council for Pharmacy Education (ACPE), and ACPE-accredited providers, the CPE Monitor Service allows you to electronically keep track of continuing pharmacy education (CPE) credits from ACPE-accredited providers. ACPE-accredited providers, like ACCP, are responsible for transmitting this information to NABP to be stored in the CPE Monitor system. Statements of credit will be available at CPE Monitor, nabp.pharmacy/cpe-monitor-service/, within 2–3 business days after completion of this activity. For more information on CPE Monitor please visit nabp.pharmacy/cpe-monitor-service/.

To transfer these credits to CPE Monitor on your behalf your NABP e-Profile ID Number and date of birth must be listed on your ACCP account. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Some international pharmacists do not use the CPE Monitor service. To verify or update this information in your ACCP account, visit Licensure/Certification. Check the box “I am an international pharmacist or I am not licensed to practice in the United States, and do not have an NABP e-Profile ID.” Be sure to save your changes at the bottom of the page.

Recertification Credit
BCACP Credit   BCGP Credit

To be eligible to earn BCACP and BCGP recertification credit, participants must purchase the recertification version of this course, review all content, successfully complete, submit and pass the Web-based posttest associated with each module by December 12, 2023. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

The passing point to earn BCACP and BCGP recertification credit is based on an expert analysis of the assessment items in each posttest module. Any posttest submitted before the Specialty Recertification Credit posttest deadline that meets this passing point will earn BCACP and BCGP recertification credits. These credits will be assigned as of the date of test submission. For statements of recertification credit, visit www.bpsweb.org.

All participants must have a Board of Pharmacy Specialties (BPS) board certification credential number, BPS ID Number, and a BPS expiration date on file with ACCP for reporting purposes. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Questions regarding the number of hours required for BCACP or BCGP recertification should be directed to BPS at (202) 946-5026 or www.bpsweb.org.

Technical Requirements
Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.

Fees
Specialty Recertification
Offers up to 6.0 continuing pharmacy education credits/recertification credits
 

Includes:

  • streaming audio/slide synchronized presentations
  • downloadable mp3 audio files
  • downloadable mp4 video files
  • downloadable/printable PDFs of presentation slides
  • online posttest(s) for CPE/Recertification credit
  • Recertification Credit Deadline: December 12, 2023
Price: $250.00 Member: $150.00

 

Please note that the posttest will not be available until December 14, 2022.